Patents by Inventor Sylvain Mareschal

Sylvain Mareschal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and kits for classifying diffuse large B-cell lymphomas (DLBCLs) into GCB-DLBCLs or into ABC-DLBCLs
    Patent number: 10519508
    Abstract: The present invention relates to a method for classifying a diffuse large B-cell lymphoma (DLBCL) of a subject into a GCB-DLBCL or into a ABC-DLBCL comprising the step of determining the expression level of 10 genes in a tumor tissue sample obtained from the subject by performing a Reverse Transcriptase Multiplex Ligation dependent Probe Amplification (RT-MLPA) assay wherein the 10 genes are NEK6, IRF4, IGHM, LMO2, FOXP1, TNFRSF9, BCL6, TNFRSF13B, CCND2 and MYBL1.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: December 31, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Rouen, Centre Henri Becquerrel
    Inventors: Fabrice Jardin, Philippe Ruminy, Sylvain Mareschal, Vinciane Marchand, Cristina Bagacean
  • Methods and Kits for Classifying Diffuse Large B-Cell Lymphomas (DLBCLs) Into GCB-DLBCLs or Into ABC-DLBCLs
    Publication number: 20170016074
    Abstract: The present invention relates to a method for classifying a diffuse large B-cell lymphoma (DLBCL) of a subject into a GCB-DLBCL or into a ABC-DLBCL comprising the step of determining the expression level of 10 genes in a tumor tissue sample obtained from the subject by performing a Reverse Transcriptase Multiplex Ligation dependent Probe Amplification (RT-MLPA) assay wherein the 10 genes are NEK6, IRF4, IGHM, LMO2, FOXP1, TNFRSF9, BCL6, TNFRSF13B, CCND2 and MYBL1.
    Type: Application
    Filed: March 10, 2015
    Publication date: January 19, 2017
    Inventors: Fabrice Jardin, Philippe Ruminy, Sylvain Mareschal, Vinciane Marchand, Cristina Bagacean